Prolactin excess: Treatment and toxicity

Pediatric Endocrinology Reviews

Volumn 2, Issue SUPPL. 1, 2004, Pages 108-114

  Gillam, Mary P ^a   Fideleff, Hugo ^b   Boquete, Hugo R ^b   Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b T Alvarez Hospital   (Argentina)

Author keywords

Adolescent; Bromocriptine; Cabergoline; Hyperprolactinemia; Pediatric; Pergolide; Prolactinoma; Quinogolide

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE; QUINAGOLIDE;

ABDOMINAL PAIN; ADOLESCENT DISEASE; ADULT DISEASE; ANEMIA; CLINICAL TRIAL; CONSTIPATION; DELUSION; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EDEMA; FETOTOXICITY; FEVER; FLU LIKE SYNDROME; FLUSHING; GASTRITIS; HEADACHE; HOT FLUSH; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; HYPOMANIA; HYPONATREMIA; INSOMNIA; LEUKOPENIA; LEUKORRHEA; MASTALGIA; NAUSEA; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PERSONALITY DISORDER; PLACENTAL TRANSFER; PROLACTINOMA; PSYCHOSIS; RASH; REVIEW; RHINITIS; SIDE EFFECT; SOMNOLENCE; TERATOGENICITY; THROMBOEMBOLISM; VASOSPASM; VOMITING;

ADULT; CHILD; DOPAMINE AGONISTS; HUMANS; HYPERPROLACTINEMIA; PITUITARY NEOPLASMS; PROLACTINOMA;

EID: 12344268726     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Colao A, Lombardi G, Annunziato L. Cabergoline. Expert Opin Pharmacother 2000;1:555-74
2. Fideleff HL, Boquete HR, Sequera A, Suarez M, Sobrado P, Giaccio A. Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches. J Pediatr Endocrinol Metab 2000;13:261-7
3. Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol 2001;11:435-40
4. Vallar L, Meldolesi J. Mechanisms of signal transduction at the dopamine D2 receptor. Trends Pharmacol Sci 1989;10:74-7
5. Wood DF, Johnston JM, Johnston DG. Dopamine, the dopamine D2 receptor and pituitary tumours. Clin Endocrinol (Oxf) 1991;35:455-66
6. Enjalbert A, Bockaert J. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Mol Pharmacol 1983;23:576-84
7. McDonald WM, Sibley DR, Kilpatrick BF, Caron MG. Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors. Mol Cell Endocrinol 1984;36:201-9
8. Caccoveili L, Cussac D, Pellegrini I, Audinot V, Jaquet P, Enjalbert A. D2 dopaminergic receptors: normal and abnormal transduction mechanisms. Norm Res 1992;38:78-83
9. Martinez de la Escalera G, Weiner RI. Effect of dopamine withdrawal on activation of adenylate cyclase and phospholipase C in enriched lactotrophs. Endocrinology 1988;123:1682-7
10. Vallar L, Vicentini LM, Meldolesi J. Inhibition of inositol phosphate production is a late, Ca2+-dependent effect of D2 dopaminergic receptor activation in rat lactotropn cells. J Biol Chem 1988;263:10127-34
11. Maurer RA. Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP. Nature 1981;294:94-7
12. Johansen PW, Clausen OP, Haug E, Fossum S, Gautvik KM. Effects of bromocriptine on cell cycle distribution and cell morphology in cultured rat pituitary adenoma cells. Acta Endocrinol (Copenh) 1985;110:319-28
13. Johansen PW, Haug E, Gautvik KM. Effects of bromocriptine on hormone production and cell growth in cultured rat pituitary cells. Acta Endocrinol (Copenh) 1985;110:200-6
14. Lloyd HM, Meares JD, Jacobi J. Effects of oestrogen and bromocryptine on in vivo secretion and mitosis in prolactin cells. Nature 1975;255:497-8
15. Lloyd HM, Jacobi JM, Willgoss DA. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine. Clin Endocrinol (Oxf) 1995;43:79-85
16. MacLeod RM, Lehmeyer JE. Suppression of pituitary tumor growth and function by ergot alkaloids. Cancer Res 1973;33:849-55
17. Brocas H, van Coevorden A, Seo H, Refetoff S, Vassart G. Dopaminergic control of prolactin mRNA accumulation in the pituitary of the male rat. Mol Cell Endocrinol 1981;22:25-30
18. Gen M, Uozumi T, Ohta M, Ito A, Kajiwara H, Mori S. Necrotic changes in prolactinomas after long term administration of bromocriptine. J Clin Endocrinol Metab 1984;59:463-70
19. Trouillas J, Chevallier P, Claustrat B, Hooghe-Peters E, Dubray C, Rousset B, Girod C. Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat. Endocrinology 1994;134:401-10
20. Molitch ME. Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 1999;28:143-69, vii
21. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985;60:698-705
22. Vance ML, Evans WS, Thorner MO. Drugs five years later. Bromocriptine. Ann Intern Med 1984;100:78-91
23. Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 1985;313:656-9
24. Bergh T, Nillius SJ, Wide L. Bromocriptine treatment of seven women with primary amenorrhoea and prolactin-secreting pituitary tumours. Clin Endocrinol (Oxf) 1979;10:145-54
25. Blackwell RE, Younger JB. Long-term medical therapy and follow-up of pediatric-adolescent patients with prolactin-secreting macroadenomas. Fertil Steril 1986;45:713-6
26. Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998;83:2777-80
27. Cannavo S, Venturino M, Curto L, De Menis E, D'Arrigo C, Tita P, Billeci D, Trimarchi F. Clinical presentation and outcome of pituitary adenomas in teenagers. Clin Endocrinol (Oxf) 2003;58:519-27
28. Howlett TA, Wass JA, Grossman A, Plowman PN, Charlesworth M, Touzel R, Rees LH, Savage MO, Besser GM. Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: response to medical therapy. Clin Endocrinol (Oxf) 1989;30:131-40
29. Tyson D, Reggiardo D, Sklar C, David R. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy. Am J Dis Child 1993;147:1057-61
30. Goldstein M, Lieberman A, Lew JY, Asano T, Rosenfeld MR, Makman MH. Interaction of pergolide with central dopaminergic receptors. Proc Natl Acad Sci U S A 1980;77:3725-8
31. Lamberts SW, Quik RF. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J Clin Endocrinol Metab 1991;72:635-41
32. Horowitz BL, Hamilton DJ, Sommers CJ, Bryan RN, Boyd AE, 3rd. Effect of bromocriptine and pergolide on pituitary tumor size and serum prolactin. AJNR Am J Neuroradiol 1983;4:415-7
33. Kendall-Taylor P, Hall K, Johnston DG, Prescott RW. Reduction in size of prolactin-secreting tumours in men treated with pergolide. Br Med J (Clin Res Ed) 1982;285:465-7
34. Kleinbers DL, Boyd AE, 3rd, Wardlaw S, Frantz AG, George A, Bryan N, Hilal S, Greising J, Hamilton D, Seltzer T, Sommers CJ. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med 1983;309:704-9
35. Kletzky OA, Sorenstein R, Mileikowsky GN. Pergolide and bromocriptine for the treatment of patients with hyperprolactinemia. Am J Obstet Gynecol 1986;154:431-5
36. L'Hermite M, Debusschere PM, Gillet C, Deschepper C. Treatment of hyperprolactinaemic patients with pergolide. Acta Endocrinol (Copenh) 1983;103:441-5
37. Franks S, Horrocks PM, Lynch SS, Butt WR, London DR. Treatment of hyperprolactinaemia with pergolide mesylate; acute effects and preliminary evaluation of long-term treatment. Lancet 1981;2:659-61
38. Freda PU andreadis CI, Khandji AG, Khoury M, Bruce JN, Jacobs TP, Wardlaw SL. Long-term treatment of prolactin-secreting macroadenomas with pergolide. J Clin Endocrinol Metab 2000;85:8-13
39. Orrego JJ, Chandler WF, Barkan AL. Pergolide as primary therapy for macroprolactinomas. Pituitary 2000;3:251-6
40. Ahmed SR, Shalet SM. Discordant responses of protactinoma to two different dopamine agonists. Clin Endocrinol (Oxf) 1986;24:421-6
41. Berezin M, Avidan D, Baron E. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs. Isr J Med Sci 1991;27:375-9
42. DiSalle E, Ornati G, Giudici D. A comparison of the in vivo and in vitro duration of prolactin lowering effect in rats of FCE 21336, pergolide and bromocriptine., Italian Society of Endocrinology: 11th National Congress, Modena, 1984. Vol. 7 (Suppl 1). J Endocrinol Invest.
43. Benedetti MS, Dostert P, Barone D, Efthymiopoulos C, Peretti G, Roncucci R. In vivo interaction of cabergotine with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine. Eur J Pharmacol 1990;187:399-408
44. Andreotti AC, Pianezzola E, Persiani S, Pacciarini MA, Strolin Benedetti M, Pontiroli AE. Pharmacokinetics, pharmacodynamics and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0 and 1.5 milligrams) in healthy male volunteers. J Clin Endocrinol Metab 1995;80:841-5
45. Ferrari C, Barbieri C, Caldara R, Mucci M, Codecasa F, Paracchi A, Romano C, Boghen M, Dubini A. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 1986;63:941-5
46. Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 2002;11:787-800
47. De Menis E, Visentin A, Billeci D, Tramontin P, Agostini S, Marton E, Conte N. Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases. J Endocrinol Invest 2001;24:92-7
48. Krassas GE, Pontikides N, Kaltsas T. Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline. Norm Res 1999;52:45-8
49. Fideleff HL, Holland ME, Chervin A, Gurucharri C, Sinai I. [Treatment of hyperprolactinemic amenorrhea with cabergoline]. Medicina (B Aires) 1997;57:657-61
50. Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A, Martin PM, Jaquet P, Brue T. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002;87:581-8
51. Fideleff HL, Ruibal G, Boquete H, Pujol A, Sequera A, Sobrado P. Macroprolactinemia in childhood and adolescence: a cause of asymptomatic hyperprolactinemia. Horm Res 2000;53:16-9
52. Fahie-Wilson MN, Ahlquist JA. Hyperprolactinaemia due to macroprolactins: some progress but still a problem. Clin Endocrinol (Oxf) 2003;58:683-5
53. Venetikou MS, Burrin JM, Woods CA, Yeo TH, Brownell J, Adams EF. Effects of two novel dopaminergic drugs, CV 205-502 and CQP 201-403, on prolactin and growth hormone secretion by human pituitary tumours in vitro. Acta Endocrinol (Copenh) 1987;116:287-92
54. Gaillard RC, Brownell J. Hormonal effects of CV 205-502, a novel octahydrobenzo [g] quinoline with potent dopamine agonist properties. Life Sci 1988;43:1355-62
55. Vance ML, Cragun JR, Reimnitz C, Chang RJ, Rashef E, Blackwell RE, Miller MM, Molitch ME. CV 205-502 treatment of hyperprolactinemia. J Clin Endocrinol Metab 1989;68:336-9
56. Rasmussen C, Brownell J, Bergh T. Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502. Acta Endocrinol (Copenh) 1991;125:170-6
57. van der Lely AJ, Brownell J, Lamberts SW. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab 1991;72:1136-41
58. Barnett PS, Palazidou E, Miell JP, Coskeran PB, Butler J, Dawson JM, Maccabe J, McGregor AM. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502. QJ Med 1991;81:891-906
59. Jasonni VM, Raffelli R, de March A, Frank G, Flamigni C. Vaginal bromocriptine in hyperprolactinemic patients and puerperal women. Acta Obstet Gynecol Scand 1991;70:493-5
60. Wass JA, Thorner MO, Besser GM. Letter: Digital vasospasm with bromocriptine. Lancet 1976;1:1135
61. Bende M, Bergman B, Sjogren C. Nasal mucosal congestion after treatment with bromocriptine. Laryngoscope 1993;103:1142-4
62. Turner TH, Cookson JC, Wass JA, Drury PL, Price PA, Besser GM. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Br Med J (Clin Res Ed) 1984;289:1101-3
63. Le Feuvre CM, Isaacs AJ, Frank OS. Bromocriptine-induced psychosis in acromegaly. Br Med J (Clin Res Ed) 1982;285:1315
64. Proctor AW. Bromocriptine-induced psychosis in acromegaly. Br Med J (Clin Res Ed) 1983;286:50
65. Pearson KC. Mental disorders from low-dose bromocriptine. N Engl J Med 1981;305:173
66. Perovich RM, Lieberman JA, Fleischhacker WW, Alvir J. The behavioral toxicity of bromocriptine in patients with psychiatric illness. J Clin Psychopharmacol 1989;9:417-22
67. Afshar F, Thomas A. Bromocriptine-induced cerebrospinal fluid rhinorrhea. Surg Neurol 1982;18:61-3
68. Aronoff SL, Daughaday WH, Laws ER, Jr. Bromocriptine treatment of prolactinomas. N Engl J Med 1979;300:1391
69. Baskin DS, Wilson CB. CSF rhinorrhea after bromocriptine for prolactinoma. N Engl J Med 1982;306:178
70. Landolt AM. Cerebrospinal fluid rhinorrhea: a complication of therapy for invasive prolactinomas. Neurosurgery 1982;11:395-401
71. Leong KS, Foy PM, Swift AC, Atkin SL, Hodden DR, MacFarlane IA. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol (Oxf) 2000;52:43-9
72. Kok JG, Bartelink AK, Schulte BP, Smals A, Pieters G, Meyer E, Merx H. Cerebrospinal fluid rhinorrhea during treatment with bromocriptine for prolactinoma. Neurology 1985;35:1193-5
73. Eickman FM. Recurrent myocardial infarction in a postpartum patient receiving bromocriptine. Clin Cardiol 1992;15:781-3
74. Giampietro O, Ferdeshini M, Petrini M. Severe leukopema and mild thrombocytopenia after chronic bromocriptine (CB-154) administration. Am J Med Sci 1981;281:169-72
75. Marshall AW, Jakobovits AW, Morgan MY. Bromocriptine-associated hyponatraemia in cirrhosis. Br Med J (Clin Res Ed) 1982;285:1534-5
76. Blackard WG. Edema-an infrequently recognized complication of bromocriptine and other ergot dopaminergic drugs. Am J Med 1993;94:445
77. Larrazet F, Spaulding C, Lobreau HJ, Weber S, Guerin F. Possible bromocriptine-induced myocardial infarction. Ann Intern Med 1993;118:199-200
78. Gilbert DL, Dure L, Sethuraman G, Raab D, Lane J, Sallee FR. Tic reduction with pergolide in a randomized controlled trial in children. Neurology 2003;60:606-11
79. Lanier WL. Additional insights into pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:684-6
80. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77:1280-6
81. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994;331:904-9
82. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84:2518-22
83. Rains CP, Bryson HM, Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 1995;49:255-79
84. Ciccarelli E, Giusti M, Miola C, Potenzoni F, Sgnedom D, Camanni F, Giordano G. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab 1989;69:725-8
85. Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J, Enjalbert A, Jaquet P. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992;74:577-84
86. Shoham Z, Homburg R, Jacobs HS. CV 205-502-effectiveness, tolerability and safety over 24-month study. Fertil Steril 1991;55:501-6
87. Homburg R, West C, Brownell J, Jacobs HS. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia. Clin Endocrinol (Oxf) 1990;32:565-71
88. Giusti M, Porcella E, Carraro A, Cuttica M, Valenti S, Giordano G. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients. J Endocrinol Invest 1994;17:51-7
89. Assies J, Verhoeff NP, Bosch DA, Hofland LJ. Intracranial dissemination of a macroprolactinoma. Clin Endocrinol (Oxf) 1993;38:539-46
90. Krupp P, Monka C, Richter K. The safety aspects of infertility treatments, Program of the Second World Congress of Gynecology and Obstetrics, Rio de Janeiro, 1988
91. Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 1987;65:823-7
92. Raymond JP, Goldstein E, Konopka P, Leleu MF, Merceron RE, Loria Y. Follow-up of children born of bromocriptine-treated mothers. Horm Res 1985;22:239-46
93. Ruiz-Velasco V, Tolis G. Pregnancy in hyperprolactinemic women. Fertil Steril 1984;41:793-805
94. Konopka P, Raymond JP, Merceron RE, Seneze J. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 1983146:935-8
95. Canales ES, Garcia IC, Ruiz JE, Zarate A. Bromocriptine as prophylactic therapy in prolactinoma during pregnancy. Fertil Steril 1981;36:524-6
96. Buelke-Sam J, Byrd RA, Johnson JA, Tizzano JP, Owen NV. Developmental toxicity of the dopamine agonist pergolide mesylate in CD-1 mice. I: Gestational exposure. Neurotoxicol Teratol 1991;13:283-95
97. De Mari M, Zenzola A, Lamberti P. Antiparkinsonian treatment in pregnancy. Mov Disprd 2002;17:428-9
98. Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A, Rocchi F, Gangi E, Paracchi S, Gasperi M, Layezzari M, Nicolosi AE, Ferrero S, Landi ML, Beck-Peccoz P, Bonati M. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002;16:791-3
99. Pharmacia and Upjohn I. Data on File, 1997
100. Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996;10:333-7
101. Musolino NRC, Bronstein MD. Prolactinomas and pregnancy. In: Bronstein MD, ed. Pituitary Tumors and Pregnancy. Norwell: Kluwer Academic Publishers, 2001:91-108
102. Liu C, Tyrrell JB. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy. Pituitary 2001;4:179-85
103. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P. Proiactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 1996;135:413-20
104. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 1996;14:228-38